Jonathan M. Meyer | Psychiatrist.com

Article

Antipsychotic Safety and Efficacy Concerns

Letter to the Editor

Article Commended

Letter to the Editor

Clinical Manifestations of Dystonia and Dyskinesia After SSRI Administration

Article

Effects of Atypical Antipsychotics on Weight and Serum Lipid Levels

Original Research

The Moderating Impact of Ethnicity on Metabolic Outcomes During Treatment With Olanzapine and Aripiprazole in Patients With Schizophrenia

Original Research

Prevalence of Hepatitis A, Hepatitis B, and HIV Among Hepatitis C-Seropositive State Hospital Patients: Results From Oregon State Hospital

Original Research

A Retrospective Comparison of Weight, Lipid, and Glucose Changes Between Risperidone- and Olanzapine-Treated Inpatients: Metabolic Outcomes After 1 Year

Commentary

Schizophrenia: The Role of Dopamine and Glutamate

Article

Strategies for the Long-Term Treatment of Schizophrenia: Real-World Lessons From the CATIE Trial

Educational Activity

Sexual Dysfunction in Patients Treated With Atypical Antipsychotics

Educational Activity

The Glutamate Hypothesis of Schizophrenia

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

InfoPack

How to Interpret Findings Concerning Newly Approved Antipsychotic Agents: Clinical Implications of the Lurasidone PEARL 2 Study

Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management

CME Institute Showcase

Non-Dopaminergic Mechanisms for Schizophrenia Symptom Management

Next generation therapeutics that work well, are better tolerated, and lead to improved outcomes may offer a different treatment approach for patients with schizophrenia.